Outlook Therapeutics Inc
NASDAQ:OTLK 1:18:45 PM EDT
| Market Cap (Intraday) | 369.78M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.14 |
| 50-Day MA | $2.31 |
| 200-Day MA | $2.24 |
Outlook Therapeutics Inc Stock, NASDAQ:OTLK
485 Route 1 South, Building F, Suite 320, Iselin, New Jersey 08830
United States of America
Phone: +1.609.619.3990
Number of Employees: 8
Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.